{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:09:27Z","timestamp":1781824167369,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Many real\u2010world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population\u2010based predictors for survival in patients diagnosed with mPDAC in a broader setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data between 1 January 2017 and 31 December 2019 were extracted from the Flatiron Health EHR database. Treatment\u2010specific predictive models were generated for patients treated with first\u2010line gemcitabine+nab\u00adpaclitaxel (GNP), FOLFIRINOX, gemcitabine monotherapy (gem\u2010mono), and second\u2010line liposomal irinotecan\u2010based regimens. The holdout method was used for cross\u2010validation. Age at diagnosis, sex, BMI, smoking status, and ECOG performance score were included in all models with additional demographic, clinical characteristics, and hematological function assessed for inclusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 3625 patients, 43% received GNP, 26% received FOLFIRINOX, 7% received gem\u2010mono, and 23% received other regimens; 40% (<jats:italic>n<\/jats:italic>\u00a0=\u00a01448) advanced to the second line. Among all first\u2010line patients, the following were included in the final model: prior surgery, white blood cell (WBC) counts, serum albumin (SA), liver function tests (LFTs), serum bilirubin, serum carbohydrate antigen 19\u20139, and ascites. Models for patients receiving specific therapies differed from the overall model, GNP (ascites removed), FOLFIRINOX (stage at initial diagnosis added), and gem\u2010mono (LFTs omitted). Alkaline phosphatase (ALP), SA, and WBC counts were important predictors of survival among patients treated with second\u2010line liposomal irinotecan. Across all regimens, the strongest predictors of survival were ECOG score, SA, and ALP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this real\u2010world study of patients with mPDAC, important population prognostic factors of survival were identified in a large cohort of patients receiving systemic treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4415","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T07:50:18Z","timestamp":1637653818000},"page":"8934-8943","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real\u2010world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-2672","authenticated-orcid":false,"given":"Kenneth H.","family":"Yu","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Ozer","sequence":"additional","affiliation":[{"name":"Capital Health Medical Center Trenton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cockrum","sequence":"additional","affiliation":[{"name":"Ipsen Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-7219","authenticated-orcid":false,"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Chul","family":"Chu","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"Cancer facts and figures 2020","author":"American Cancer Society","year":"2020"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004215"},{"key":"e_1_2_12_5_1","unstructured":"National Cancer Institute (SEER).Surveillance Epidemiology and End Results (SEER) program. Cancer stat facts: pancreatic cancer. Accessed 11\/22\/2020."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv295"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2477"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5714"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171362"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0784-z"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.007"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0014"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9636"},{"key":"e_1_2_12_17_1","unstructured":"NCCN Guidelines Version 1.2021 Pancreatic Adenocarcinoma 2020. Available from URL:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103283"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5101-3"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0681-y"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06945-8"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071798"},{"key":"e_1_2_12_23_1","unstructured":"Flatiron.Life sciences. Accessed April 14 2021.https:\/\/Flatiron.com\/real\u2010world\u2010evidence\/"},{"key":"e_1_2_12_24_1","article-title":"Comparison of population characteristics in real\u2010world clinical oncology databases in the US. Flatiron Health, SEER, and NPCR","author":"Ma X","year":"2020","journal-title":"Medrxiv"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000012186"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225657.30803.9d"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.131"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.131"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1953-y"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.23984"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S154599"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0786"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.11.001"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5810-x"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:03:47Z","timestamp":1693199027000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":34,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cam4.4415"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4415","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"2021-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}